Neimeth International Pharmaceuticals Plc has reversed a loss-making trend, posting a profit after tax (PAT) of N982 million for the year ended 31 December 2025, compared with a loss of N885.33 million in 2024.
The company’s revenue surged to N7.37 billion, up 64 per cent from N4.49 billion in the previous year, driven by improved sales performance. Cost of sales increased to N4.02 billion, generating a gross profit of N3.35 billion, a 71 per cent increase from N1.96 billion in 2024. Operating profit jumped to N2.71 billion from just N18.89 million the previous year, reflecting a strong operational turnaround.
Brandspur Banking News Desk reports that Neimeth also recorded a foreign exchange gain of N48.11 million, a major recovery from a N2.05 billion loss in 2023. Finance costs were reduced to N1.22 billion from N873.32 million, contributing further to profitability. Earnings per share rose to 22.98 kobo from a loss per share of 20.72 kobo in 2024.
On the balance sheet, total assets increased to N14.93 billion from N11.99 billion, while total liabilities rose to N12.30 billion from N10.34 billion, leaving net assets at N2.63 billion, up from N1.65 billion.
Earlier in 2025, Neimeth had posted an 11 per cent increase in profit for the half-year ended 30 June, with a PAT of N219.6 million compared with N198.2 million for the same period in 2024, signalling consistent growth throughout the year.
The pharmaceutical firm’s turnaround reflects improved operational efficiency, cost management, and favourable market conditions, marking a significant recovery for one of Nigeria’s long-standing pharmaceutical companies.
